Learn about NRC’s new, innovative Health Technologies Program, offering pre-clinical medical device research and product development solutions that will get you the results you need – faster time to market and earlier sales. We provide product development and testing services, access to NRC infrastructure and industry focused strategic R&D projects. NRC also provides in select areas state-of- the-art, patent protected technological solutions that may be integrated to a client’s proprietary product, providing additional product differentiation in target markets. Our offering is focused on the following segments: in Vitro Diagnostics, in Vivo Devices, Implantable Devices, Simulation and Digital Health.
For more information, please see:
http://www.nrc-cnrc.gc.ca/eng/solutions/collaborative/health_tech_index.html
BIOGRAPHY
Dr. Jean-Francois Houle joined the NRC as Director of Research and Development for the Medical Devices Portfolio in June 2014. He also leads its Health Technologies Program which supports Canadian medical device companies in their quest for new sources of productivity, competitive advantage and growth by providing customized research and technology solutions. Prior to joining the NRC, Dr.Houle had spent 14 years leading business, corporate and product development activities in private and public biotechnology firms at various stages of development from University spin-offs to more established companies. Most recently, as COO of Kapplex, he guided the company through its initial spin-out of the University of Toronto into a full-fledged funded start-up. Prior to Kapplex, Dr. Houle held a leadership role in product and business development at Axela, a company in the field of multiplexed biomarker detection, leading the successful launch of several products. Dr. Houle began his industrial career at SYNX Pharma, a proteomics and diagnostics company, where he sought out, structured and fostered collaborations and alliances. These activities led to a diagnostic development agreement with Ortho-Clinical Diagnostics and the eventual merger of SYNX with Nanogen Inc. JF holds a Ph.D. in Experimental Medicine from McGill University and holds several patents in the field of biomarker detection.